Related Experiment Video
Updated: Nov 3, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Lack of Relationship between Fibrosis-Related Biomarkers and Cardiac Magnetic Resonance-Assessed Replacement and
Paweł Rubiś1, Ewa Dziewięcka1, Magdalena Szymańska2
1Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital, Pradnicka St. 80, 31-202 Krakow, Poland.
Insights
Circulating fibrosis markers do not predict cardiac fibrosis in dilated cardiomyopathy (DCM). Cardiac-specific markers like NT-proBNP and troponin T showed associations with fibrosis, suggesting limited utility for fibrosis markers in DCM diagnosis.
Area of Science:
- Cardiology
- Biomarker Research
- Medical Imaging
Background:
- Dilated cardiomyopathy (DCM) involves complex cardiac remodeling.
- The link between circulating fibrosis markers and cardiac fibrosis in DCM is not well-established.
- Accurate assessment of cardiac fibrosis is crucial for DCM management.
Purpose of the Study:
- To investigate the association between circulating fibrosis-related molecules and cardiac fibrosis quantified by cardiac magnetic resonance imaging (CMR) in DCM patients.
- To compare biomarker levels in DCM patients with varying degrees of replacement and interstitial fibrosis.
- To determine the diagnostic and monitoring utility of circulating fibrosis markers in DCM.
Main Methods:
- Prospective, single-center observational study of 100 DCM patients.
- Cardiac fibrosis assessed using late gadolinium enhancement (LGE) for replacement fibrosis and extracellular volume (ECV) for interstitial fibrosis via CMR.
- Plasma concentrations of multiple fibrosis biomarkers and cardiac-specific markers (NT-proBNP, hs-TnT) were measured.
Main Results:
- No circulating fibrosis biomarkers were associated with LGE or ECV in DCM patients.
- NT-proBNP was independently associated with both LGE and ECV.
- Troponin T (hs-TnT) was associated with ECV.
- Circulating fibrosis markers did not differentiate between patients with or without replacement fibrosis or stratified by median ECV.
Conclusions:
- Circulating fibrosis markers lack utility in diagnosing or monitoring cardiac fibrosis in DCM.
- Cardiac-specific biomarkers, NT-proBNP and hs-TnT, show associations with cardiac fibrosis, warranting further investigation.
- Current circulating fibrosis markers are not reliable indicators of myocardial fibrosis burden in DCM.
Abstract:
The relationship between circulating fibrosis-related molecules and magnetic resonance-assessed cardiac fibrosis in dilated cardiomyopathy (DCM) is poorly understood. To compare circulating biomarkers between DCM patients with high and low fibrosis burdens, we performed a prospective, single-center, observational study. The study population was composed of 100 DCM patients (87 male, mean age 45.2 ± 11.8 years, mean ejection fraction 29.7% ± 10.1%). Replacement fibrosis was quantified by means of late gadolinium enhancement (LGE), whereas interstitial fibrosis was assessed via extracellular volume (ECV). Plasma concentrations of cardiotrophin-1, growth differentiation factor-15, platelet-derived growth factor, procollagen I C-terminal propeptide, procollagen III N-terminal propeptide, and C-terminal telopeptide of type I collagen were measured. There were 44% patients with LGE and the median ECV was 27.7%. None of analyzed fibrosis serum biomarkers were associated with the LGE or ECV, whereas NT-proBNP was independently associated with both LGE and ECV, and troponin T was associated with ECV. None of the circulating fibrosis markers differentiated between DCM patients with and without replacement fibrosis, or patients stratified according to median ECV. However, cardiac-specific markers, such as NT-proBNP and hs-TnT, were associated with fibrosis. Levels of circulating markers of fibrosis seem to have no utility in the diagnosis and monitoring of cardiac fibrosis in DCM.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis I: Introduction
Heart Failure II: Pathophysiology

